Driving Toward Better Schizophrenia Care: Finding Another Route in a Complex Disease With Long-Acting Injectable Medications

This dynamic CME program blends interactive case consultations with a data-driven deep dive into long-acting injectables (LAIs) for schizophrenia. Through engaging real-world scenarios, learners will explore barriers and biases that influence LAI utilization and discover communication strategies that foster shared decision-making with patients and caregivers. A comprehensive evidence review highlights innovative LAIs, their attributes, and the latest clinical trial findings, offering practical insights for treatment planning. This unique format equips clinicians with both the knowledge and the skills to optimize adherence, improve outcomes, and confidently integrate LAIs into patient care.
 

Upon completion of this activity, participants should be able to:

• Identify the factors that contribute to suboptimal utilization of LAIs for the treatment of patients with schizophrenia 
• Employ impartial, person-centered communication strategies to LAI treatment discussions with patients with schizophrenia and their caregivers
• Describe the nuances of second-generation LAIs for the treatment of schizophrenia, including pharmacology, drug characteristics, and available clinical and real-world evidence

Nurse Practitioner Continuing Education 

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

PA Continuing Education 

PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Paradigm requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months.

All relevant relationships are identified and mitigated according to Paradigm policy prior to individuals assuming their roles and are disclosed prior to learners’ engagement in the activity. Paradigm is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The content of this activity was independently reviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated.

Leslie Citrome, MD, MPH
Consultant: Acadia Pharmaceuticals Inc.; Adamas Pharmaceuticals, Inc; AdhereTech LLC; Allergan, Inc.; Alkermes; Alumis Inc.; Angelini Pharma S.p.A.; Astellas Pharma US, Inc; Autobahn Therapeutics; Axsome Therapeutics, Inc.; Biogen; BioXcel Therapeutics Inc.; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Cerevel Therapeutics; Clinilabs; Compass Therapeutics, Inc.; Delpor, Inc.; Draig Therapeutics; Eisai Inc.; Enteris BioPharma; HLS Therapeutics Inc.; Idorsia Pharmaceuticals Ltd; Impel Pharmaceuticals; INmuneBIO; Janssen Pharmaceuticals, Inc; Johnson & Johnson Services, Inc; Lundbeck; Luye Pharma Group; Lyndra Therapeutics; MapLight; Marvin Pharma Ltd; MedAvante-ProPhase; Merck & Co, Inc; Mitsubishi Tanabe Pharma; Neumora; Neurelis, Inc; Neurocrine Biosciences, Inc.; Noema Pharma; Novartis AG; Noven Pharmaceuticals, Inc.; Otsuka America Pharmaceuticals, Inc; Ovid Therapeutics; Praxis Precision Medicines, Inc.; Recordati; Relmada Therapeutics; Reviva Pharmaceuticals; Sage Therapeutics, Inc; Sumitomo Corporation; Supernus Pharmaceuticals, Inc.; Teva Pharmaceutical Industries Ltd; Vanda Pharmaceuticals
Speakers’ Bureau: Acadia Pharmaceuticals Inc.; Allergan, Inc; Alkermes; Angelini Pharma S.p.A.; Axsome Therapeutics, Inc.; BioXcel Therapeutics Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc; Johnson & Johnson Services, Inc; Lundbeck; Neurocrine Biosciences, Inc.; Neopharm Labs; Noven Pharmaceuticals, Inc.; Otsuka America Pharmaceuticals, Inc; Recordati; Sage Therapeutics, Inc; Sumitomo Corporation; Takeda Pharmaceutical Company Ltd; Teva Pharmaceutical Industries Ltd; Vanda Pharmaceuticals 
Stocks: Bristol-Myers Squibb Company; Eli Lilly and Company; Johnson & Johnson Services, Inc; Merck & Co, Inc; Pfizer Inc; Reviva Pharmaceuticals

Christoph U. Correll, MD
Advisor: AbbVie Inc.; Alkermes; Allergan, Inc.; Angelini Pharma; Boehringer Ingelheim International GmbH;  Bristol-Myers Squibb Company; Cerevel Therapeutics; Compass; CSL Seqirus; Gedeon Richter Plc; Janssen Pharmaceuticals, Inc; Johnson & Johnson; Karuna Therapeutics; LB Pharmaceuticals; Life Science Therapeutics; Lundbeck; Medincell; Merck & Co, Inc; Neuraxpharm; Neurelis; Neurocrine Biosciences; Newron Pharmaceuticals SpA; Novo Nordisk A/S; Otsuka America Pharmaceuticals, Inc; Recordati SpA; ROVI Pharma Industrial Services, S.A.; Sage Therapeutics, Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Teva Pharmaceutical Industries Ltd; Vertex Pharmaceuticals Incorporated; Viatris Inc.
Consultant: AbbVie Inc.; Alkermes; Angelini Pharma; Autobahn Therapeutics; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Cerevel Therapeutics; CNX Therapeutics; Compass; CSL Seqirus; Darnitsa Pharmaceuticals; Delpor, Inc.; Draig Therapeutics; Eli Lilly and Company; EuMentis Therapeutics; Gedeon Richter Plc; GH Research; Hikma Pharmaceuticals PLC; Holmusk; Intra-Cellular Therapies; Janssen Pharmaceuticals, Inc; Johnson & Johnson; LB Pharmaceuticals; Lundbeck; MapLight Therapeutics, Inc.; Medincell; MedLink Global; Merck & Co, Inc; Mindpax; Mylan N.V.; Neumora Therapeutics, Inc.; Neuraxpharm; Neurelis; Neurocrine Biosciences; Neurosterix; NeuShen Therapeutics, Inc.; Newron Pharmaceuticals SpA; Noven Pharmaceuticals, Inc.; Novo Nordisk A/S; Orion Corporation; Otsuka America Pharmaceuticals, Inc; PPD Biotech Solutions; Recognify Life Sciences, Inc; Recordati SpA; Relmada Therapeutics, Inc.; Response Pharmaceuticals Inc.; Reviva Pharmaceuticals Holdings, Inc; ROVI Pharma Industrial Services, S.A.; Saladax Biomedical, Inc.; Sanofi; Servier Pharmaceuticals LLC; Sunovion Pharmaceuticals Inc; Sun Pharmaceutical Industries Ltd; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Ltd; Teva Pharmaceutical Industries Ltd; Terran Biosciences; Tolmar, Inc.; Vertex Pharmaceuticals Incorporated; Viatris Inc.; Xenon Pharmaceuticals Inc.
Research Funding: Boehringer Ingelheim International GmbH; Janssen Pharmaceuticals, Inc; Takeda Pharmaceutical Company Ltd
Royalties: Wolters Kluwer
Stocks: Kuleon Bioscience; LB Pharmaceuticals; MedLink Global; Mindpax; Quantic
Other (Honoraria): AbbVie Inc.; Angelini Pharma; Aristo Pharma; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Cerevel Therapeutics; CSL Seqirus;  Gedeon Richter Plc; Hikma Pharmaceuticals PLC; Intra-Cellular Therapies; Janssen Pharmaceuticals, Inc; Johnson & Johnson; Karuna Therapeutics; Lundbeck; Mitsubishi Tanabe Pharma America; Mylan N.V.; Otsuka America Pharmaceuticals, Inc; Recordati SpA; Sanofi; Sunovion Pharmaceuticals Inc; Tabuk Pharmaceuticals; Takeda Pharmaceutical Company Ltd; Teva Pharmaceutical Industries Ltd; Viatris Inc.
Other (Expert Testimony): Janssen Pharmaceuticals, Inc; Lundbeck; Neurocrine Biosciences; Otsuka America Pharmaceuticals, Inc
Other (DSMB): Compass; Intra-Cellular Therapies; Relmada Therapeutics, Inc.; Reviva Pharmaceuticals Holdings, Inc; ROVI Pharma Industrial Services, S.A.

Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies to disclose.

Independent peer reviewer has no relevant financial relationships with ineligible companies to disclose.